Hikma Pharmaceuticals

Pharmaceuticals
HIK.L
GBX 1,284 (1.4)%
Share price
$ 3.2 bn
Market Cap
$ 4.6 bn
Enterprise Value

Carbon footprint

25 Ton
GHG emissions per $ 1 mln investment
0.67x the weighted average for S&P 500
FY2021
How is this calculated?
-20%
YOY change in GHG emissions
Weaker than the +5% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-0.8%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Hikma Pharmaceuticals aims to reduce Scope 1 + 2 by 25% by 2030 from a base year 2020

This target is most likely outdated and the company appears to have already achieved it
This target has not been verified as science based according to SBTi
Hikma Pharmaceuticals's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Hikma Pharmaceuticals's GHG emissions (market-based) (Kt of CO2e)
Hikma Pharmaceuticals's Carbon intensity (Tons per 1 USDm)

Hikma Pharmaceuticals's carbon footprint

Hikma Pharmaceuticals reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 117 Kt (-28 /-19.5% y-o-y). Also positively, carbon intensity decreased to 46 t (-16 /-26.2% y-o-y).

Hikma Pharmaceuticals's Scope 3 emissions grew to 830 Kt (+829/+104124% y-o-y).

The company is committed to reducing Scope 1 + 2 by 25% by 2030 from a base year 2020, which it appears to have already achieved as of 2021. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...